Inici › Mieloma múltiple › Maryland › Baltimore
Assaigs clínics de Mieloma múltiple a Baltimore, MD
13 estudis de Mieloma múltiple busquen participants en centres de Baltimore i voltants (en un radi d'uns 30 milles). Obre un estudi per veure qui hi pot participar i com contactar amb l'equip.
Text oficial de l'estudi (anglès)
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
ReclutantFase 3
- Johns Hopkins Hospital, Baltimore
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
ReclutantFase 3
- University of Maryland School of Medicine, Baltimore
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
ReclutantFase 3
- Johns Hopkins University School of Medicine JHUSOM, Baltimore
Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies
ReclutantFase 1 inicial
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
ReclutantFase 3
- Johns Hopkins Asthma & Allergy Center, Baltimore
Collection of Tissue Samples for Cancer Research
ReclutantEstudi observacional
- Johns Hopkins University, Baltimore
A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma
ReclutantFase 3
- University of Maryland | Greenebaum Cancer Center, Baltimore
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
ReclutantFase 3
- Research Site, Baltimore
A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
ReclutantFase 1
- University of Maryland Greenbaum Comprehensive Cancer Center, Baltimore
Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
ReclutantFase 3
- Greater Baltimore Medical Center, Baltimore
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
ReclutantFase 3
- Greenebaum Cancer Center UM of MD, Baltimore
- John Hopkins, Baltimore
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
ReclutantFase 1/2
- Sibley Memorial Hospital, Baltimore
- University of Maryland, Baltimore
- Johns Hopkins Main Center, Baltimore
A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma
ReclutantFase 1/2
- Johns Hopkins Medicine - The Sidney Kimmel Comprehensive Cancer Center, Baltimore
Assaigs de Mieloma múltiple en altres ciutats
- New York City, NY60 estudis
- Boston, MA42 estudis
- Atlanta, GA41 estudis
- Houston, TX38 estudis
- Durham, NC37 estudis
- Nashville, TN32 estudis
- Denver, CO27 estudis
- Rochester, MN24 estudis
- St. Louis, MO24 estudis
- Columbus, OH24 estudis
- Baldwin Park, CA23 estudis
- Chicago, IL22 estudis
Altres estudis a Baltimore
- Càncer de pulmó de cèl·lules no petites60 estudis
- Càncer de mama47 estudis
- Càncer de pròstata43 estudis
- Càncer de pulmó40 estudis
- Càncer (tots els tipus)37 estudis
- Càncer colorrectal31 estudis
- Càncer de pàncrees31 estudis
- Càncer metastàtic28 estudis
- Obesitat25 estudis
- Insuficiència cardíaca24 estudis
- Càncer de bufeta24 estudis
- Ictus22 estudis
De ClinicalTrials.gov, dades recuperades el 5 d’oct. 2026. Cada estudi estableix els seus propis criteris d'elegibilitat; l'equip de l'estudi decideix qui hi pot participar.